CONDOR trial finds brolucizumab better preserves vision than laser in proliferative diabetic retinopathy
May 20, 2026
The CONDOR randomized clinical trial found brolucizumab better preserved visual acuity than panretinal photocoagulation in proliferative diabetic retinopathy at week 54. Brolucizumab also reduced vision-threatening complications and center-involved diabetic macular edema events, while showing more intraocular inflammation.